Navigation Links
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Date:2/17/2011

halmic solution)– Ophthalmologic DiseasesVEGF Trap-Eye is a fusion protein locally administered in the eye that is designed to bind Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PLGF), proteins that are involved in the abnormal growth of new blood vessels.  Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.  Bayer HealthCare LLC has rights to market VEGF Trap-Eye outside the United States, where the companies will share equally in profits from any future sales of VEGF Trap-Eye.

Phase 3 studies in wet age-related macular degeneration

In November 2010, Regeneron and Bayer Healthcare reported positive one-year data from two Phase 3 studies (VIEW 1 and VIEW 2) evaluating VEGF Trap-Eye in patients with the neovascular form of age-related macular degeneration (wet AMD).  Based on these results, Regeneron plans to submit a Biologics License Application to the Food and Drug Administration (FDA) for marketing approval in the U.S. in the first half of 2011.  In addition, Bayer Healthcare intends to submit regulatory applications in the first half of 2011 for marketing approval in Europe.

In VIEW 1 and VIEW 2, VEGF Trap-Eye was administered either monthly or every two months, and compared to monthly doses of ranibizumab, which is the current standard of care in wet AMD.  In these studies, all regimens of VEGF Trap-Eye including VEGF Trap-Eye dosed every two months successfully met the primary endpoint of non-inferiority compared to ranibizumab dosed every month.  The primary endpoint was statistical non-inferiority in the proportion of patients who maintained (or improved) vision over 52 weeks compared to ranibizumab.  At least 94% of patients in every VEGF Trap-Eye group, including those dosed every two months, as well as those receiving ranibizumab dosed monthly, maintained visual acuity over 52 weeks.  Visual acuity was measured as a score based on the
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014  Sage Analytics ( www.sageanalytics.com ), ... for the testing of marijuana potency and moisture ... Luminary™ Profiler, the industry,s first product suite capable ... cost-effective, portable unit. Designed from the ... the cannabis industry, the Luminary™ Profiler utilizes specially ...
(Date:12/19/2014)... , Dec. 18, 2014 Baptist Health Lexington is ... to receive full Atrial Fibrillation with Electrophysiology Services (EPS) ... Atrial fibrillation is the most common cardiac arrhythmia ... some cases can lead to stroke and possible death. More ... have atrial fibrillation and the numbers are rapidly ...
(Date:12/19/2014)... membrane market has witnessed robust development with the growth pace ... later starter. In 2012, the size of China ... the proportion worldwide soaring to 16.3%. It is projected that ... its growth rate by around 20% in the upcoming years ... RMB25 billion. An integrated membrane industrial system has ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... 2011 Nephros, Inc. (OTC Bulletin Board: NEPHD ... for therapeutic applications, infection control, and water purification, announced today ... December 31, 2010. 2010 Highlights ... prior year period Increased gross margin by 22% to ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... a proposal to the Board of Directors of Cephalon, ... for $73.00 per share in cash.  The proposal, valued ... 29% over Cephalon,s 30-day trading average.  Valeant announced its ...
Cached Medicine Technology:Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 2Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 3Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 4Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 5Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 6Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 7Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 8Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 9Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 2Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 3Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 4Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 5Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 6Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 7Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 8Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 9Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 10Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 11Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 12
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... 19, 2014 Silver Dollar City ... record -- for the first time ever, Silver Dollar City ... Guinness World Records 2015, listing the park’s wood coaster Outlaw ... In additional awards announced this week, Silver Dollar City is ... in the US,” USA Today’s 10Best awards for “Best Public ...
(Date:12/19/2014)... December 19, 2014 Eufaula, Oklahoma, located ... Lake Eufaula, the state’s largest lake with more than ... is home to a little more than 3,000 residents, ... on Saturday, the 6th of December. , Featuring Santa, ... through downtown Eufaula on Main Street. Narconon Arrowhead’s ...
(Date:12/19/2014)... An evening dress is perfect for any occasion and ... distinguished dresses retailer, has unveiled its new selection of evening ... great shopping platform. Customers can view more at ... has been accepted and praised by customers for many years. ... for clients. In order to expand its market share, the ...
(Date:12/19/2014)... The print component of Vision and Hearing is ... Toronto Star, with a circulation of approximately 230,433 copies ... is distributed nationally through a vast social media strategy ... partner outlets. To explore the digital version of the ... an exclusive interview with Mark DeMontis , sharing ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2
... investigators Lewis C. Cantley, PhD, and Cornelius P. Terhorst, PhD, ... American Association for the Advancement of Science. They are ... distinguished efforts to advance science, and will be honored during ... BIDMC,s Division of Signal Transduction and Director of the BIDMC ...
... This release is available in German . ... of recovery depending on disease stage. Experts hope that the ... is more helpful in the choice of the right treatment ... for Quality and Efficiency in Health Care (IQWiG) has now ...
... 2011 HIV-positive head and neck cancer patients respond ... rates as non-HIV-positive patients, despite prior reports to the ... of the International Journal of Radiation OncologyBiologyPhysics , ... Oncology (ASTRO). , Patients with HIV have a significantly ...
... The combined results of a genetic blood test and ... of healthy older adults, many of whom were destined ... John Woodard, Ph.D., associate ... and Sciences and Institute of Gerontology at Wayne State ...
... (Jan. 19, 2011) A new program designed to create ... Colorado has received a $3.9 million grant from the Colorado ... four-year program housed in the Department of Family Medicine at ... brings together local and national leaders from the mental health, ...
... Dotinga HealthDay Reporter , TUESDAY, Jan. 18 (HealthDay ... that aims to reveal the presence of Alzheimer,s disease, potentially ... early stages. Another study finds that blood tests could indicate ... there,s a catch: Alzheimer,s disease is not curable, and existing ...
Cached Medicine News:Health News:Malignant brain tumors: Benefit of PET and PET/CT in the detection of recurrences is not assessable 2Health News:HIV-positive head and neck cancer patients benefit from radiation therapy 2Health News:Wayne State University study predicts risk of memory loss in healthy, older adults 2Health News:New program targeting whole-person health care gets major grant 2Health News:Progress Reported in Predicting Alzheimer's 2
... The Albumin Cobalt Binding (ACB®) Test ... Ischemia Modified Albumin (IMA®) by measuring the ... patient serum sample. First identified in the ... albumin comes in contact with ischemic tissue ...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
Inquire...
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
Medicine Products: